rose bengal disodium
Small molecule
Evidence outlook
Phase 3 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT02288897) was terminated, and no study is currently active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02557321 NCT02557321 · Locally Advanced Cutaneous Melanoma Registry: NCT02557321 | 1/2 | Safety and tolerability of the combination regimen assessed by adverse events (AEs) (Start of treatment until 4 weeks after final administration of PV-10); Progression Free Survival (PFS) (Up to 24 months from initiation of study treatment) 2023-05 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT02288897 NCT02288897 · Locally Advanced Cutaneous Melanoma Registry: NCT02288897 | 3 | Progression-free Survival (PFS) (Assessed every 12 weeks until disease progression, withdrawal of consent, or study termination; progression detected between formal assessments was documented at the time of detection; median follow-up time for PFS was 26.6 weeks, maximum was 125.8 weeks.) 2019-04 | Progression-free Survival (PFS) (Assessed every 12 weeks until disease progression, withdrawal of consent, or study termination; progression detected between formal assessments was documented at the time of detection; median follow-up time for PFS was 26.6 weeks, maximum was 125.8 weeks.): PV-10 6.1 Months (range 1.5 to 28.9) | Chemotherapy or Oncolytic Viral Therapy 8.6 Months (range 1.8 to 14.4) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.